Skip to content

Effects of robotic and thoracoscopic lobectomy on trauma and lymphocyte subsets in patients with non-small cell lung cancer

Effects of robotic and thoracoscopic lobectomy on trauma and lymphocyte subsets in patients with non-small cell lung cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026425
Enrollment
Unknown
Registered
2019-10-09
Start date
2019-10-09
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Robot surgery group:Robotic lobectomy
Thoracoscopic surgery group:Thoracoscopic lobectomy

Sponsors

Army Medical Center of PLA (Daping Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Preoperative image data was considered as non-small cell lung cancer, without obstructive pneumonia and surgical treatment was proposed; 2) Age: more than 18 years old and less than 70 years old; 3) No immunosuppressant was used before surgery, and no hormones or no immunomodulator drugs were used before. 4) No immunodeficiency diseases such as AIDS, systemic lupus erythematosus, leukemia, etc.; 5) No radiotherapy or chemotherapy before surgery; 6) No serious others diseases, refractory hypertension, old large-area myocardial infarction, moderate to severe chronic obstructive pulmonary disease and so on; 7) Actively cooperate with preoperative and postoperative treatment.

Exclusion criteria

Exclusion criteria: 1) Patients whose surgical method is not radical lobectomy; 2) Patients with intraoperative and postoperative pathological diagnosis of benign tumor or small cell lung cancer 3) Dense and extensive pleural adhesion (more than 50%) was found during operation, 4) Converse surgical method to thoracotomy during operation; 5) Tumor invade in more than one lobectomy, requiring multilobectomy or central lung cancer; 6) Intraoperative and postoperative blood transfusion; 7) Patients who refuse relevant treatment and have incomplete clinical data records for various reasons.

Design outcomes

Primary

MeasureTime frame
lymphocyte subsets;Hospitalization costs;

Secondary

MeasureTime frame
leukocyte count;neutrophil count;C-Reactive Protein;interleukin-6;Operation times (min);Operation blood loss (ml);Number of lymph node dissection stations;Numbers of lymph node dissection;Drainage duration (days);Drainage flow (ml);Postoperative hospital stay (days);postoperative complications;Pain scor;

Countries

China

Contacts

Public ContactQunyou Tan

Army Medical Center of PLA (Daping Hospital)

Tanqy001@163.com+86 023-68757986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026